Hancock Whitney Reports Third Quarter 2023 EPS of $1.12
GULFPORT, Miss.–(BUSINESS WIRE)–Hancock Whitney Corporation (Nasdaq: HWC) today announced its financial results for the third quarter of 2023. Net income... Read more.
Arcus Biosciences to Present Data from Ongoing EDGE-Gastric Study at ASCO Plenary and to Report Third-Quarter Financial Results on November 7
Data from the A1 cohort of EDGE-Gastric, the Phase 2 study of domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, in first-line upper gastrointestinal cancers... Read more.
Procurant Signs Schnucks for Perishables Order Management and Produce Inspections
New system brings speed, efficiency and enhanced data to buyers and their network of perishable goods suppliers. WATSONVILLE, Calif.–(BUSINESS WIRE)–#freshfood–Procurant,... Read more.
KBRA Assigns Preliminary Ratings to Towd Point Mortgage Trust 2023-CES2 (TPMT 2023-CES2)
NEW YORK–(BUSINESS WIRE)–#KBRA–KBRA assigns preliminary ratings to 34 classes of asset-backed securities from Towd Point Mortgage Trust 2023-CES2... Read more.
KBRA Assigns Preliminary Ratings to FHF Trust 2023-2
NEW YORK–(BUSINESS WIRE)–#KBRA–KBRA assigns preliminary ratings to four classes of notes issued by FHF Trust 2023-2 (“FHF 2023-2”), a subprime... Read more.
Neoadjuvant Opdivo (nivolumab) with Chemotherapy Provides Benefits for Patients with Resectable Non-Small Cell Lung Cancer Across PD-L1 Expression Levels with Three-Year Follow Up in CheckMate -816 Trial
Regardless of PD-L1 expression levels, neoadjuvant Opdivo with chemotherapy showed a greater reduction in the risk of disease recurrence, progression or death than... Read more.
Groundbreaking Advancement in Minimally Invasive Bunion Surgery (MIBS): Voom Medical Devices Introduces Next Generation, Functionally Distinctive Patented Screw
NEW YORK–(BUSINESS WIRE)–#bunionplasty–Voom™ Medical Devices, Inc. (“Voom”), a rapidly growing orthopedic medical device company with a primary... Read more.
Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Followed by Opdivo Demonstrates Significant Survival Benefits for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in Phase 3 CheckMate -901 Trial
Opdivo in combination with cisplatin-based chemotherapy followed by Opdivo monotherapy reduced the risk of death by 22% for patients with unresectable or metastatic... Read more.
Downtown Mesa Revitalization Progress Continues With Opening of 2nd Avenue Commons Housing Development
New Complex Brings Attainable Workforce Housing Solutions to a Booming Region of Maricopa County SCOTTSDALE, Ariz.–(BUSINESS WIRE)–#AlternativeInvestment—CaliberCos... Read more.
Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Shows Significant Improvement in Event-Free Survival for Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -77T Trial
Neoadjuvant Opdivo with chemotherapy followed by surgery and adjuvant Opdivo reduced the risk of disease recurrence, progression or death by 42% in patients with... Read more.